Evidence map›Paper›PMID 41737212›Full record

ArticleFrontiers in immunology2026

Mincle-dependent Th17 adjuvanticity requires TNFR1 signaling in myeloid cells.

Robert Blamberg, Carl Haberkamp, Gabriel Kristian Pedersen, Ida Rosenkrands, Ulrike Schleicher, Barbara U Schraml, Sho Yamasaki, Roland Lang

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Robert BlambergInstitute of Clinical Microbiology, Immunology and Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Carl HaberkampInstitute of Clinical Microbiology, Immunology and Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Gabriel Kristian PedersenCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
Ida RosenkrandsCenter for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark.
Ulrike SchleicherInstitute of Clinical Microbiology, Immunology and Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Barbara U SchramlBiomedical Center Munich, Institute of Immunology, Faculty of Medicine, Ludwig-Maximilians-Universität München, Planegg-Martinsried, Germany.
Sho YamasakiDepartment of Molecular Immunology, Research Institute for Microbial Diseases (RIMD), Osaka University, Suita, Japan.
Roland LangInstitute of Clinical Microbiology, Immunology and Hygiene, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Successful induction of protective T cells by recombinant protein vaccines requires adjuvants. The liposomal adjuvant system CAF01 induces robust Th17 responses in mice. CAF01 contains the synthetic glycolipid trehalose-6,6-dibehenate (TDB), whose recognition by the C-type lectin receptor Mincle is required for Th17 induction. In previous work, we identified a pivotal role of TNF in upregulation of Mincle expression in macrophages and Th17 adjuvanticity of CAF01. The question has remained on which cell type(s) TNF acts to mediate the Th17 adjuvanticity of CAF01, and whether TNF-induced Mincle upregulation is causative. We used conditional TNFR1-deficient mice to dissect cell type-specific contributions of TNF signaling in myeloid cells, DC and T cells to Th17 induction by the recombinant tuberculosis fusion protein H1 adjuvanted with CAF01. LysM-Cre-mediated deletion of TNFR1 on myeloid cells completely abrogated vaccine-induced Th17 differentiation, replicating the phenotype in mice deficient in TNF or treated with the TNF blocker Etanercept. In contrast, TNFR1 deletion in DC by Clec9a-Cre did not affect Th17 induction, and by CD11c-Cre only partially reduced Th17 cells. T cell-specific deletion of TNFR1 by Lck-Cre had no impact on Th17 differentiation after vaccination. TNFR1 was expressed highly, and deleted efficiently via LysM-Cre, in monocytes and in neutrophils. We recently showed that neutrophils are not required for the adjuvant effect of CAF01, but monocytes are essential. Therefore, we analyzed activation of monocytes by TDB and observed robust upregulation of Mincle expression and of the Th17-inducing cytokines IL-1β and IL-6, that was inhibited by Etanercept. Finally, we asked whether Th17 induction by TNF is causally linked to Mincle upregulation. Constitutive, TNF-independent transgenic Mincle expression partially restored Th17 induction by CAF01 despite TNF blockade. Thus, upregulation of Mincle by TNF plays a causal role, likely by enabling production of Th17-polarizing cytokines by myeloid cells upon enhanced sensing of the adjuvant component TDB.

Indexed as

Adjuvants, ImmunologicLectins, C-TypeMembrane ProteinsMyeloid CellsReceptors, Tumor Necrosis Factor, Type ISignal TransductionTh17 CellsAnimalsCell DifferentiationDendritic CellsMiceMice, Inbred C57BLMice, KnockoutTumor Necrosis Factor-alphaAdjuvants, ImmunologicClecsf8 protein, mouseLectins, C-TypeMembrane ProteinsReceptors, Tumor Necrosis Factor, Type ITnfrsf1a protein, mouseTumor Necrosis Factor-alphaCAF01MincleTDBTDMTh17TNFTNFR1vaccination

Identifiers

PMID41737212
PMCPMC12926142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.